Home » Stocks » ATNX

Athenex, Inc. (ATNX)

Stock Price: $11.11 USD -0.55 (-4.72%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 1.04B
Revenue (ttm) 156.94M
Net Income (ttm) -118.41M
Shares Out 83.71M
EPS (ttm) -1.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $11.11
Previous Close $11.66
Change ($) -0.55
Change (%) -4.72%
Day's Open 11.60
Day's Range 11.07 - 11.63
Day's Volume 475,887
52-Week Range 5.71 - 15.52

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel thera...

GlobeNewsWire - 1 week ago

BUFFALO, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel thera...

Zacks Investment Research - 1 month ago

Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.

GlobeNewsWire - 1 month ago

BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel thera...

GlobeNewsWire - 1 month ago

BUFFALO, N.Y., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel thera...

GlobeNewsWire - 2 months ago

BUFFALO, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therap...

Zacks Investment Research - 2 months ago

Athenex (ATNX) delivered earnings and revenue surprises of 4.35% and 81.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer

Zacks Investment Research - 2 months ago

Athenex (ATNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 2 months ago

These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.

Other stocks mentioned: COLL
GlobeNewsWire - 2 months ago

BUFFALO, N.Y., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapi...

PRNewsWire - 3 months ago

BUFFALO, N.Y. and CHICAGO, Oct. 9, 2020 /PRNewswire/ -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...

GlobeNewsWire - 3 months ago

Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S. Athenex’s first T cell therapy product cleared to advance to the first stage of...

The Motley Fool - 4 months ago

The company announced the pricing of a public offering of common stock.

GlobeNewsWire - 4 months ago

BUFFALO, N.Y., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...

GlobeNewsWire - 4 months ago

BUFFALO, N.Y., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...

GuruFocus - 4 months ago

The Dow Jones Industrial Average closed at 29,100.50 on Wednesday with a gain of 454.84 points or 1.59%.

Other stocks mentioned: CAL, CORT, DXC, TWTR
Zacks Investment Research - 4 months ago

The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021.

Zacks Investment Research - 4 months ago

Athenex (ATNX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

The Motley Fool - 4 months ago

The company announced good news regarding one of its leading pipeline candidates.

GlobeNewsWire - 4 months ago

FDA grants Priority Review and sets PDUFA target action date of February 28, 2021

Seeking Alpha - 5 months ago

Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Athenex (ATNX) delivered earnings and revenue surprises of -32.26% and 89.49%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

BUFFALO, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel thera...

GlobeNewsWire - 5 months ago

Regulatory progress for Oral Paclitaxel and tirbanibulin ointment is on track

GlobeNewsWire - 5 months ago

Pharmaceutical industry veteran with significant oncology clinical development expertise appointed to Board Pharmaceutical industry veteran with significant oncology clinical development exper...

Zacks Investment Research - 5 months ago

Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

BUFFALO, N.Y., July 27, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel thera...

GlobeNewsWire - 6 months ago

BUFFALO, N.Y., June 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel thera...

GlobeNewsWire - 6 months ago

BUFFALO, N.Y., June 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and com...

PRNewsWire - 7 months ago

BUFFALO, N.Y. and CHICAGO, June 13, 2020 /PRNewswire/ -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of nove...

Zacks Investment Research - 8 months ago

Athenex (ATNX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 8 months ago

Athenex (ATNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

Athenex, Inc. (ATNX) CEO Dr.

Benzinga - 8 months ago

Shares of Athenex (NASDAQ:ATNX) fell 4.8% after the company reported Q1 results. Quarterly Results Earnings per share were up 54.72% year over year to ($0.24), which missed the estimate of ($0...

Zacks Investment Research - 8 months ago

Athenex (ATNX) delivered earnings and revenue surprises of -14.29% and 46.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Athenex, Inc. (ATNX).

GlobeNewsWire - 8 months ago

BUFFALO, N.Y., April 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...

GlobeNewsWire - 9 months ago

BUFFALO, N.Y., April 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...

GlobeNewsWire - 10 months ago

BUFFALO, N.Y., March 13, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...

GlobeNewsWire - 10 months ago

PDUFA date of December 30, 2020 PDUFA date of December 30, 2020

Zacks Investment Research - 10 months ago

Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 10 months ago

BUFFALO, N.Y., March 02, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...

Zacks Investment Research - 10 months ago

Athenex (ATNX) delivered earnings and revenue surprises of 44.00% and 185.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 11 months ago

BUFFALO, N.Y., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Today, Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex, Inc. (Nasdaq: ATNX), informed shareholders he received a notice of a...

Seeking Alpha - 11 months ago

A Small Bet On Athenex

Zacks Investment Research - 1 year ago

Athenex, Inc. (ATNX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Seeking Alpha - 1 year ago

Athenex: Compelling Overall Survival Advantage For Oral Paclitaxel, Revaluation In Progress

Seeking Alpha - 1 year ago

Elite is on track to become profitable for the first time

Other stocks mentioned: LCI

About ATNX

Athenex, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Ora... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jun 14, 2017
CEO
Johnson Lau
Employees
574
Stock Exchange
NASDAQ
Ticker Symbol
ATNX
Full Company Profile

Financial Performance

In 2019, Athenex's revenue was $101.23 million, an increase of 13.61% compared to the previous year's $89.10 million. Losses were -$123.75 million, 5.37% more than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Athenex stock is "Buy." The 12-month stock price forecast is 27.41, which is an increase of 146.71% from the latest price.

Price Target
$27.41
(146.71% upside)
Analyst Consensus: Buy